177LU-PSMA IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER: PRELIMINARY ANALYSIS OF A BRAZILIAN MULTICENTRIC STUDY by Victor Cabral Costa Ribeiro Heringer, Felipe P.G. Ribeiro, Diogo Bastos, Camila Mosci, Dalton A. Anjos, Paulo Almeida Filho, Gustavo Gomes, Filipe Villela-Pedras, Fabio Ribeiro, Julio Correia, José F. Marin, Carlos Buchpiguel, Elba C.S.C. Etchebehere

Subjects: “…177Lu-PSMA…”
Get full text

The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials by Alexander Konopnicki, Michael Zaliznyak, Mathews Roy, Bagi Jana

Subjects: Get full text

Validation of dosimetry programs (Olinda & IDAC) for evaluation of absorbed dose in 177LuPSMA therapy of metastatic castration-resistant prostate cancer (mCRPC) using Monte Carlo s... by Sirwan Maroufpour, Kamran Aryana, Shahrokh Nasseri, Zahra Fazeli, Hossein Arabi, Mehdi Momennezhad

Subjects: Get full text

Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management by Sonia Mahajan, Ravinder K. Grewal, Kent P. Friedman, Heiko Schöder, Neeta Pandit-Taskar

Subjects: “…177Lu-PSMA-617…”
Get full text

Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT by Dagmar Grob, Bastiaan M. Privé, Constantijn H. J. Muselaers, Niven Mehra, James Nagarajah, Mark W. Konijnenberg, Steffie M. B. Peters

Subjects: Get full text

177LU-PSMA AND 177LU-DOTATATE AS THERAPY ALTERNATIVES FOR METACHRONOUS TRANSDIFFERENTIATED PROSTATE AND NEUROENDOCRINE TUMORS - CASE REPORT by Beatriz Birelli do Nascimento, Elson Yassunaga Teshirogi, Lucas Bueno Oliveira, Lucas Nascimento Bernardes, Walter Stefatuno, Braulio Regiani Passos

Subjects: Get full text

Early treatment response assessment with [177Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET by David Ventura, Philipp Rassek, Philipp Schindler, Burak Han Akkurt, Linus Bredensteiner, Martin Bögemann, Katrin Schlack, Robert Seifert, Michael Schäfers, Wolfgang Roll, Kambiz Rahbar

Subjects: “…[177Lu]PSMA…”
Get full text

External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies by J. Kurth, B. J. Krause, S. M. Schwarzenböck, L. Stegger, M. Schäfers, K. Rahbar

Subjects: “…177Lu-PSMA…”
Get full text

Extraordinary therapeutic effect of PSMA radioligand therapy in treatment-refractory progressive metastatic prostate cancer with the transketolase inhibitor benfo-oxythiamine as a... by Carsten S. Kramer, Jingjing Zhang, Richard P. Baum

Subjects: Get full text

All that glitters is not gold: high uptake on PSMA PET in non-prostate cancers does not mean that treatment with [177Lu]Lu-PSMA-radioligand will be successful by Trond Velde Bogsrud, Ola Engelsen, Thuy Thu Thi Lu, Andreas Stensvold, Derek R. Johnson, Brian J. Burkett, Ayse Tuba Kendi, Mukesh K. Pandey, Rune Sundset, Jolanta M. Durski

Subjects: “…[177Lu]-PSMA-RL…”
Get full text

A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR) by David Kryza, Armelle Vinceneux, Anne-Sophie Bidaux, Gwenaelle Garin, Delphine Tatu, Claire Cropet, Jean-Noël Badel, David Perol, Anne-Laure Giraudet

Subjects: “…177Lu-PSMA-1…”
Get full text

Determination of Optimum Imaging Numbers for 177Lu-PSMA Radionuclide Treatment Dosimetric Calculation by Bilal Kovan

Subjects: Get full text

Localized radiotherapy of solid tumors using radiopharmaceutical loaded implantable system: insights from a mathematical model by Anahita Piranfar, Mohammad Souri, Arman Rahmim, Arman Rahmim, Madjid Soltani, Madjid Soltani, Madjid Soltani, Madjid Soltani, Madjid Soltani

Subjects: Get full text

Quantification of biochemical PSA dynamics after radioligand therapy with [177Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model by Hinke Siebinga, Berlinda J. de Wit-van der Veen, Daphne M. V. de Vries-Huizing, Wouter V. Vogel, Jeroen J. M. A. Hendrikx, Alwin D. R. Huitema

Subjects: “…177Lu-PSMA-I&T…”
Get full text

Performance of ChatGPT-4 and Bard chatbots in responding to common patient questions on prostate cancer 177Lu-PSMA-617 therapy by Gokce Belge Bilgin, Cem Bilgin, Daniel S. Childs, Jacob J. Orme, Brian J. Burkett, Ann T. Packard, Derek R. Johnson, Matthew P. Thorpe, Irbaz Bin Riaz, Thorvardur R. Halfdanarson, Geoffrey B. Johnson, Geoffrey B. Johnson, Oliver Sartor, Oliver Sartor, Oliver Sartor, Ayse Tuba Kendi

Subjects: Get full text

Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer by Daniel Groener, Cam Tu Nguyen, Justus Baumgarten, Benjamin Bockisch, Karen Davis, Christian Happel, Nicolai Mader, Christina Nguyen Ngoc, Jennifer Wichert, Severine Banek, Philipp Mandel, Felix K. H. Chun, Nikolaos Tselis, Frank Grünwald, Amir Sabet

Subjects: Get full text

Organ and tumor dosimetry including method simplification for [177Lu]Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer by Amir Karimzadeh, Linus Schatz, Markus Sauer, Ivayla Apostolova, Ralph Buchert, Susanne Klutmann, Wencke Lehnert

Subjects: Get full text

Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression? by Felix Kind, Kerstin Michalski, Elham Yousefzadeh-Nowshahr, Philipp T. Meyer, Michael Mix, Juri Ruf

Subjects: Get full text

Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trialResearch in context by Ken Herrmann, Andrei Gafita, Johann S. de Bono, Oliver Sartor, Kim N. Chi, Bernd J. Krause, Kambiz Rahbar, Scott T. Tagawa, Johannes Czernin, Ghassan El-Haddad, Connie C. Wong, Zhaojie Zhang, Celine Wilke, Osvaldo Mirante, Michael J. Morris, Karim Fizazi

Subjects: Get full text

177Lu-PSMA radioligand therapy for isolated bilateral adrenal metastases from prostate cancer by Elisabetta Perrone, Kriti Ghai, Aleksandr Eismant, Kornelia Konz, Richard P. Baum

Subjects: Get full text